Akèy › Kansè nan tete › Michigan
Etid klinik pou Kansè nan tete nan Michigan
74 etid pou Kansè nan tete ap chèche patisipan nan sit nan Michigan.
Vil nan Michigan
- Detroit33 etid
- Ann Arbor26 etid
- Grand Rapids25 etid
- Lansing10 etid
- Farmington Hills10 etid
- Flint9 etid
- Warren9 etid
- Waterford8 etid
- Clinton Township7 etid
- Wyoming6 etid
- Dearborn6 etid
- Mount Pleasant5 etid
- Saginaw5 etid
- Port Huron4 etid
- Bay City4 etid
- Midland4 etid
- Kalamazoo4 etid
- Livonia4 etid
- Jackson4 etid
- Troy4 etid
- Canton4 etid
- Sterling Heights3 etid
Tèks ofisyèl etid la (Anglè)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- ak 68 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Profound Research -OMG - TriAtria Cancer Center, Farmington Hills
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06760819A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Henry Ford Hospital, Detroit
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07102381Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- University of Michigan, Ann Arbor
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06324357Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- McLaren Proton Therapy Center, Flint
Ap rekriteFaz 2
Laj 50 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT01766297A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Henry Ford Health ( Site 0002), Detroit
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06312176A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Detroit
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06103864ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- University of Michigan Rogel Cancer Center, Ann Arbor
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07007559Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Ann Arbor
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Karmanos Cancer Center - Wayne State University, Detroit
- Cancer & Hematology Centers, Grand Rapids
- Munson Medical Center Cowell Family Cancer Center, Traverse City
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07214532A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Barbara Ann Karmanos Cancer Institute, Detroit
- BAMF Health Inc., Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07114601A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Barbara Ann Karmanos Cancer Institute, Detroit
- BAMF Health Inc., Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213791A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Henry Ford Hospital, Detroit
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05894239ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Karmanos Cancer Center, Detroit
- Profound Research LLC at Michigan Hematology and Oncology Consultants, Royal Oak
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07173751A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Karmanos Cancer Institute, Detroit
- Brigitte Harris Cancer Pavilion BHCP, Detroit
- START Midwest, LLC, Grand Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT06827236A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- The Cancer & Hematology Centers, Grand Rapids
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06492616A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
- Cancer and Leukemia Center, Sterling Heights
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 14, 2026 · NCT07541079Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Karmanos Cancer Institiute, Detroit
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- University of Michigan, Ann Arbor
- Henry Ford Cancer Institute, Detroit
- START - Midwest Cancer Research Center, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Henry Ford Hospital, Detroit
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05386108A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- Profound Research LLC at Michigan Hematology and Oncology Consultants, Royal Oak
Ap rekriteFaz 1
Laj 18 a 55 · Fanm · Mizajou Sep 9, 2026 · NCT07310420A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06400472Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Wayne State University - Barbara Ann Karmanos Cancer Institute, Detroit
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07287917Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- University of Michigan, Ann Arbor
- Profound Research LLC, Royal Oak
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06982521Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Trinity Health, Ann Arbor
Ap rekriteEtid obsèvasyon
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07211178Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial
- Trinity Health IHA - Obstetrics and Gynecology West Arbor, Ann Arbor
Ap rekriteFaz 3
Laj 22 ak plis · Fanm · Mizajou Sep 3, 2026 · NCT05379153A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Henry Ford Health System, Detroit
- Cancer & Hematology Centers of Western Michigan, Grand Rapids
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06790693The Vanguard Study: Testing a New Way to Screen for Cancer
- Henry Ford Cancer Institute-Downriver, Brownstown
- Henry Ford Health Center - Brownstown, Brownstown
- Henry Ford Health Center - Chesterfield, Chesterfield
- ak 13 plis
Ap rekriteVolontè an sante akeyi
Laj 45 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT06995898Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- ak 73 plis
Ap rekriteFaz 3
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07029399A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
- Karmanos Cancer Institute at McLaren Bay Region, Bay City
- Karmanos Cancer Institute at McLaren Clarkston, Clarkston
- Karmanos Cancer Institute, Detroit
- ak 5 plis
Ap rekrite
Laj 22 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07227831Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Wayne State University/Karmanos Cancer Institute, Detroit
- Weisberg Cancer Treatment Center, Farmington Hills
- McLaren Cancer Institute-Flint, Flint
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06500481A Study of MGC026 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT06242470A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Henry Ford Cancer- Detroit (Brigitte Harris Cancer Pavilion), Detroit
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT06926868Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
- University of Michigan Rogel Cancer Center, Ann Arbor
Ap rekriteFaz 2Volontè an sante akeyi
Laj 45 a 74 · Fanm · Mizajou Aug 4, 2026 · NCT06195306Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Karmanos Cancer Institute, Detroit
- START Midwest, Grand Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366E-Mindfulness Approaches for Living After Breast Cancer
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- ak 20 plis
Ap rekriteFaz 3
Laj 18 a 50 · Tout sèks · Mizajou Aug 4, 2026 · NCT06748222Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
- Henry Ford Health, Detroit
Ap rekriteVolontè an sante akeyi
Laj 45 a 74 · Fanm · Mizajou Jul 31, 2026 · NCT05625659Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- BAMF Health, Grand Rapids
Ap rekriteFaz 1
Laj 18 a 100 · Tout sèks · Mizajou Jul 29, 2026 · NCT06562192Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
- University of Michigan Rogel Cancer Center, Ann Arbor
Ap rekriteFaz 2
Laj 18 a 55 · Fanm · Mizajou Jul 27, 2026 · NCT06184750Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.